Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon and type 2 diabetes: the return of the alpha cell

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diabetes Management During Breastfeeding in Women with Type 1 Diabetes

    Research output: Contribution to journalReviewResearchpeer-review

  2. Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?

    Research output: Contribution to journalReviewResearchpeer-review

  3. Can Cardiovascular Epidemiology and Clinical Trials Close the Risk Management Gap Between Diabetes and Prediabetes?

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Reporting Severe Hypoglycemia in Type 1 Diabetes: Facts and Pitfalls

    Research output: Contribution to journalReviewResearchpeer-review

  5. Metabolomic Biomarkers in the Progression to Type 1 Diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Glucagon-like peptide-1 receptor regulation of basal dopamine transporter activity is species-dependent

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pregnancy loss is associated with type 2 diabetes: a nationwide case-control study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects with Hepatic Steatosis

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

In normal physiology, glucagon from pancreatic alpha cells plays an important role in maintaining glucose homeostasis via its regulatory effect on hepatic glucose production. Patients with type 2 diabetes suffer from fasting and postprandial hyperglucagonemia, which stimulate hepatic glucose production and, thus, contribute to the hyperglycemia characterizing these patients. Although this has been known for years, research focusing on alpha cell (patho)physiology has historically been dwarfed by research on beta cells and insulin. Today the mechanisms behind type 2 diabetic hyperglucagonemia are still poorly understood. Preclinical and clinical studies have shown that the gastrointestinal hormone glucose-dependent insulinotropic polypeptide (GIP) might play an important role in this pathophysiological phenomenon. Furthermore, it has become apparent that suppression of glucagon secretion or antagonization of the glucagon receptor constitutes potentially effective treatment strategies for patients with type 2 diabetes. In this review, we focus on the regulation of glucagon secretion by the incretin hormones glucagon-like peptide-1 (GLP-1) and GIP. Furthermore, potential advantages and limitations of suppressing glucagon secretion or antagonizing the glucagon receptor, respectively, in the treatment of patients with type 2 diabetes will be discussed.

Original languageEnglish
JournalCurrent Diabetes Reports
Volume14
Issue number12
Pages (from-to)555
ISSN1534-4827
DOIs
Publication statusPublished - Dec 2014

ID: 44714301